Denka Co. Ltd. (TYO:4061) announced on June 10 that it has been offered subsidies for an in-house R&D effort focused on infection testing. The company has been working here to develop and test new multiplexed diagnostics technology that targets COVID-19 alongside a range of other infections. The subsidy offer came in on May 28 from the Japan Agency for Medical…
Please subscribe to read the full story.Subscribe
Already a member? Log in here
